SMARCA 4 / BRG 1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer

Erica Hlavin Bell, PhD, Arup R. Chakraborty, PhD, Xiaokui Mo, PhD, Ziyan Liu, MS, Konstantin Shilo, MD, Simon Kirste, MD, Petra Stegmaier, MD, Maureen McNulty, BS, Niki Karachaliou, MD, Rafael Rosell, MD, PhD, Gerold Bepler, MD, PhD, David P. Carbone, MD, PhD, and Arnab Chakravarti, MD Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH, United States of America Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain Catalan Institute of Oncology, Badalona, Barcelona, Spain Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States of America Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America

[1]  P. Hammerman,et al.  EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors , 2014, Nature.

[2]  K. Coombes,et al.  Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Stephanie Huang,et al.  Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer , 2014, Genom. Proteom. Bioinform..

[4]  C. Roberts,et al.  Vulnerabilities of mutant SWI/SNF complexes in cancer. , 2014, Cancer cell.

[5]  R. Siebert,et al.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type , 2014, Nature Genetics.

[6]  P. Bunn,et al.  Recent clinical advances in lung cancer management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Yokota,et al.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.

[8]  G. Bepler,et al.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Fontanini,et al.  ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin , 2013, British Journal of Cancer.

[10]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[11]  J. Soria,et al.  ERCC1 and RRM1: ready for prime time? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Huntsman,et al.  Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics , 2013, Orphanet Journal of Rare Diseases.

[13]  M. Gong,et al.  The chromatin remodeling protein BRG1 modulates BRCA1 response to UV irradiation by regulating ATR/ATM activation , 2013, Front. Oncol..

[14]  D. Reisman,et al.  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. , 2012, Experimental cell research.

[15]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[16]  J. Lubiński,et al.  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer , 2012, Breast Cancer Research.

[17]  R. Langer,et al.  DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. , 2011, European journal of cancer.

[18]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  So-jung Kim,et al.  A cooperative activation loop among SWI/SNF, γ‐H2AX and H3 acetylation for DNA double‐strand break repair , 2010, The EMBO journal.

[20]  G. Wani,et al.  Modulation of Nucleotide Excision Repair by Mammalian SWI/SNF Chromatin-remodeling Complex* , 2009, The Journal of Biological Chemistry.

[21]  H. Greulich,et al.  Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability , 2008, Molecular and Cellular Biology.

[22]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[23]  Jun Yokota,et al.  Frequent BRG1/SMARCA4–inactivating mutations in human lung cancer cell lines , 2008, Human mutation.

[24]  Maria A Stalteri,et al.  Give me shelter: the global housing crisis. , 2003, BMC Bioinformatics.

[25]  A. Imbalzano,et al.  Mammalian SWI/SNF complexes facilitate DNA double‐strand break repair by promoting γ‐H2AX induction , 2006, The EMBO journal.

[26]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[27]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[28]  Weidong Wang,et al.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. , 2003, Cancer research.

[29]  D. Teng,et al.  BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. , 2000, Cancer research.

[30]  Shaomu Chen,et al.  Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer. , 2015, Oncology reports.

[31]  Ji-Hye Park,et al.  Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage. , 2009, DNA repair.

[32]  R. Jaksik,et al.  Calculation of reliable transcript levels of annotated genes on the basis of multiple probe-sets in Affymetrix microarrays. , 2009, Acta biochimica Polonica.

[33]  N. Hanna,et al.  Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer , 2006 .

[34]  福岡 順也.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer , 2004 .